The IL-17 signalling pathway is a major target in treatment of plaque psoriasis. IL-17 signalling contributes to chronic inflammation and epidermal hyperplasia seen in psoriatic lesions. Blocking the IL-17 signalling cascade is an effective method in treating this disease. However, IL-17 also plays a role in the immunological protection against fungal infections and therefore, patients on IL-17 biologics experience an increased rate of fungal infections, specifically Candida albicans. It is prudent that patients and physicians are aware of this risk and understand how to recognize and manage Candida infections. In this review, we examine the Candida infection rates associated with IL-17 biologics, both in clinical trials and real-world practice. We discuss common presentations associated with various types of candidiasis and propose a recommended management approach to treating these infections.
HarringtonLE.HattonRD.ManganPRet al. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123-1132.doi:10.1038/ni1254
2.
ParkH.LiZ.YangXOet al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol.2005;6(11):1133-1141.doi:10.1038/ni126116200068
3.
BoehnckeW-H. Etiology and pathogenesis of psoriasis. Rheum Dis Clin North Am.2015;41(4):665-675.doi:10.1016/j.rdc.2015.07.01326476225
IwakuraY.IshigameH.SaijoS.NakaeS. Functional specialization of interleukin-17 family members. Immunity.2011;34(2):149-162.doi:10.1016/j.immuni.2011.02.01221349428
6.
WrightJF.GuoY.QuaziAet al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem.2007;282(18):13447-13455.doi:10.1074/jbc.M70049920017355969
7.
VillanovaF.FlutterB.TosiIet al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol.2014;134(4):984-991.doi:10.1038/jid.2013.47724352038
8.
ShaoS.FangH.DangEet al. Neutrophil extracellular traps promote inflammatory responses in psoriasis via activating epidermal TLR4/IL-36R crosstalk. Front Immunol.2019;10:746.doi:10.3389/fimmu.2019.0074631024570
9.
ChiricozziA.Guttman-YasskyE.Suárez-FariñasMet al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677-687.doi:10.1038/jid.2010.34021085185
10.
BaeHC.JeongSH.KimJHet al. RIP4 upregulates CCL20 expression through STAT3 signalling in cultured keratinocytes. Exp Dermatol.2018;27(10):1126-1133.doi:10.1111/exd.1375030044012
11.
RizzoHL.KagamiS.PhillipsKG.KurtzSE.JacquesSL.BlauveltA. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol.2011;186(3):1495-1502.doi:10.4049/jimmunol.100100121172868
12.
EyerichK.FoersterS.RomboldSet al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol.2008;128(11):2640-2645.doi:10.1038/jid.2008.13918615114
13.
IshigameH.KakutaS.NagaiTet al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity.2009;30(1):108-119.doi:10.1016/j.immuni.2008.11.00919144317
14.
ContiHR.ShenF.NayyarNet al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med.2009;206(2):299-311.doi:10.1084/jem.2008146319204111
15.
NiemiecM.KapitanM.PolkeM.JacobsenI. Commensal to pathogen transition of Candida albicans; 2017.
16.
GoepfertA.LehmannS.WirthE.RondeauJ-M. The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor recognition properties. Sci Rep.2017;7(1):8906.doi:10.1038/s41598-017-08360-928827714
17.
LangleyRG.ElewskiBE.LebwohlMet al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med.2014;371(4):326-338.doi:10.1056/NEJMoa131425825007392
18.
MrowietzU.LeonardiCL.GirolomoniGet al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27-36.doi:10.1016/j.jaad.2015.04.01125982539
19.
BissonnetteR.LugerT.ThaçiDet al. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol.2017;177(4):1033-1042.doi:10.1111/bjd.1570628580579
20.
BlauveltA.PrinzJC.GottliebABet al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484-493.doi:10.1111/bjd.1334825132411
21.
GottliebAB.BlauveltA.PrinzJCet al. Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: results of the feature trial. J Drugs Dermatol.2016;15(10):1226-1234.27741340
22.
PaulC.LacourJ-P.TedremetsLet al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol.2015;29(6):1082-1090.doi:10.1111/jdv.1275125243910
23.
LacourJ-P.PaulC.JazayeriSet al. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol.2017;31(5):847-856.doi:10.1111/jdv.1407328111801
24.
GordonKB.BlauveltA.PappKAet al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med.2016;375(4):345-356.doi:10.1056/NEJMoa151271127299809
25.
GriffithsCEM.ReichK.LebwohlMet al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet.2015;386(9993):541-551.doi:10.1016/S0140-6736(15)60125-826072109
26.
BlauveltA.LebwohlMG.MabuchiTet al. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol.2021;85(2):360-368.doi:10.1016/j.jaad.2020.11.02233253833
27.
PappKA.ReichK.PaulCet al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol.2016;175(2):273-286.doi:10.1111/bjd.1449326914406
28.
LebwohlM.StroberB.MenterAet al. Phase 3 studies comparing Brodalumab with ustekinumab in psoriasis. N Engl J Med.2015;373(14):1318-1328.doi:10.1056/NEJMoa150382426422722
29.
PappK.MenterA.LeonardiCet al. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). Br J Dermatol. 2020;183(6):1037-1048.doi:10.1111/bjd.1913232286683
30.
PuigL.LebwohlM.BachelezH.SobellJ.JacobsonAA. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol.2020;82(2):352-359.doi:10.1016/j.jaad.2019.05.09531175909
31.
GordonKB.FoleyP.KruegerJGet al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet.2021;397(10273):475-486.doi:10.1016/S0140-6736(21)00126-433549192
32.
ReichK.WarrenRB.LebwohlMet al. Bimekizumab versus Secukinumab in plaque psoriasis. N Engl J Med.2021;385(2):142-152.doi:10.1056/NEJMoa210238333891380
33.
WarrenRB.BlauveltA.BagelJet al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med.2021;385(2):130-141.doi:10.1056/NEJMoa210238833891379
34.
ReichK.PappKA.BlauveltAet al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet.2021;397(10273):487-498.doi:10.1016/S0140-6736(21)00125-233549193
35.
ThaçiD.VenderR.de RieMet al. Safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis: Longer-term results from the BE SURE randomised controlled trial and the BE BRIGHT open-label extension trial. 2021.
36.
LeonardiC.SatorP.MoritaAet al. Bimekizumab efficacy and safety up to two years in patients with moderate to severe plaque psoriasis switching from ustekinumab: results from the interim BE BRIGHT open-label extension trial. presented at: EADV. 2021.
37.
GreenL.HsuS.PappK.AlexanderB.RastogiS.IsraelR. Fungal infections in patients with psoriasis during treatment with brodalumab: analysis of clinical trials. J Am Acad Dermatol.2018;79(3):AB145.
38.
DeodharA.MeasePJ.McInnesIBet al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther.2019;21(1):111.doi:10.1186/s13075-019-1882-231046809
39.
ReichK.WarrenRB.CoatesLC.Di ComiteG. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol.2020;34(6):1161-1173.doi:10.1111/jdv.1612431785165
40.
StroberB.LeonardiC.PappKAet al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J Am Acad Dermatol.2017;76(3):e17:432-440.doi:10.1016/j.jaad.2016.09.02627889292
41.
PappKA.BachelezH.BlauveltAet al. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. Br J Dermatol.2017;177(6):1537-1551.doi:10.1111/bjd.1572328600810
42.
GenoveseMC.MyslerE.TomitaTet al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology.2020;59(12):3834-3844.doi:10.1093/rheumatology/keaa18932449924
43.
ArmstrongA.PaulC.PuigLet al. Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 Patient-Years of exposure. Dermatol Ther.2020;10(1):133-150.doi:10.1007/s13555-019-00340-331749092
44.
ReichK.BlauveltA.LebwohlMet al. Bimekizumab safety in patients with moderate to severe psoriasis: analysis of pooled data from phase 2 and 3 clinical trials. SKIN The Journal of Cutaneous Medicine.2021;5(1):s21.doi:10.25251/skin.5.supp.21
45.
DavidsonL.van den ReekJMPA.BrunoMet al. Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources. Lancet Reg Health Eur.2022;13:100266.doi:10.1016/j.lanepe.2021.10026634950923
46.
NotarioJ.DezaG.VilarrasaEet al. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. J Dermatolog Treat.2019;30(5):424-429.doi:10.1080/09546634.2018.152800030244618
47.
GalluzzoM.D’AdamioS.SilvaggioD.LombardoP.BianchiL.TalamontiM. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther.2020;20(2):173-182.doi:10.1080/14712598.2020.170889731880166
48.
SrinivasC.OdsbuI.LinderM. Risk of common infections among individuals with psoriasis in Sweden: a nationwide cohort study comparing secukinumab to ustekinumab. Pharmacoepidemiol Drug Saf.2020;29(12):1562-1569.doi:10.1002/pds.513232975344
49.
LebwohlM.LeonardiC.WuJJet al. Two-year us pharmacovigilance report on Brodalumab. Dermatol Ther.2021;11(1):173-180.doi:10.1007/s13555-020-00472-x33337520
50.
SaunteDM.MrowietzU.PuigL.ZachariaeC. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol.2017;177(1):47-62.doi:10.1111/bjd.1501527580411
51.
LoftND.VaengebjergS.HallingA-S.SkovL.EgebergA. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol.2020;34(6):1151-1160.doi:10.1111/jdv.1607331721310
52.
Rodríguez-CerdeiraC.González-CespónJL.Martínez-HerreraEet al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Ital J Dermatol Venerol.2021;156(5):545-557.doi:10.23736/S2784-8671.20.06580-333026212
53.
DavidsonL.van den ReekJMPA.BrunoMet al. Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources. The Lancet Regional Health - Europe.2022;13(10217):100266.doi:10.1016/j.lanepe.2021.100266
54.
ArmstrongAW.BukhaloM.BlauveltA. A clinician’s guide to the diagnosis and treatment of candidiasis in patients with psoriasis. Am J Clin Dermatol.2016;17(4):329-336.doi:10.1007/s40257-016-0206-427435194
55.
Thomas-RüddelDO.SchlattmannP.PletzM.KurzaiO.BloosF. Risk factors for invasive Candida infection in critically ill patients: a systematic review and meta-analysis. Chest.2022;161(2):345-355.doi:10.1016/j.chest.2021.08.08134673022
56.
PappasPG.KauffmanCA.AndesDRet al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases Society of America. Clin Infect Dis.2016;62(4):e1-e50.doi:10.1093/cid/civ93326679628
57.
TaudorfEH.JemecGBE.HayRJ.SaunteDML. Cutaneous candidiasis - an evidence-based review of topical and systemic treatments to inform clinical practice. J Eur Acad Dermatol Venereol.2019;33(10):1863-1873.doi:10.1111/jdv.1578231287594
58.
KolbingerF.Di PadovaF.DeodharAet al. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacol Ther.2022;229:107925.doi:10.1016/j.pharmthera.2021.10792534171337
59.
LiuL.LuJ.AllanBWet al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res.2016;9:39-50.doi:10.2147/JIR.S10094027143947
60.
SILIQ™. (brodalumab) [package insert]. Valeant Pharmaceuticals North America LLC; 2017.
61.
FarahnikB.BeroukhimK.AbroukMet al. Brodalumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther.2016;6(2):111-124.doi:10.1007/s13555-016-0121-x27221323
62.
AdamsR.MaroofA.BakerTet al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:11.doi:10.3389/fimmu.2020.0189432973785
63.
BlauveltA.GooderhamM.IversenLet al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol.2017;77(5):855-862.doi:10.1016/j.jaad.2017.06.15328917383
64.
PuigL.BlauveltA.RamharterMet al. 25554 an integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies. J Am Acad Dermatol.2021;85(3):AB61.doi:10.1016/j.jaad.2021.06.270
65.
FerrisDG.DekleC.LitakerMS. Women’s use of over-the-counter antifungal medications for gynecologic symptoms. J Fam Pract.1996;42(6):595-600.8656170
66.
LOTRISONE®. (clotrimazole and betamethasone dipropionate). Schering Corporation; 2007.
DevarajA.O’BeirneJP.VeaseyR.DunkAA. Interaction between warfarin and topical miconazole cream. BMJ.2002;325(7355):77.doi:10.1136/bmj.325.7355.7712114237
69.
NYSTATIN. [package insert]. Morton Grove Pharmaceuticals, Inc; 2018.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
